Table 3.

Afatinib Concentration (ng/mL) in Blood at Indicated Time Points

CohortSubject IDDosingC1D8C1D15C1D22C2D1C3D1C4D1EOT
Cohort 1:
80 mg q4d
002pre8.75111.693<LLOQ (EoC2)
post12.323
003pre<LLOQ17.318
post<LLOQ30.096
004pre<LLOQ<LLOQ
post<LLOQ
Cohort 2: 120 mg q4d005pre7.18
post37.68
006pre<LLOQ10.104<LLOQ11.223
post66.156
008pre22.243
post392.01
Cohort 3: 180 mg q4d010pre43.226
post324.265
011pre11.61619.265
post11.705
012pre<LLOQ<LLOQ6.402
(EoC4)
post96.35485.834
013pre10.37441.9646.787
post
Expansion Cohort 3: 180 mg q4d014pre11.442
post60.605
017pre10.425-5.708<LLOQ6.264-
post89.884
Cohort 4: 280 mg q7d015pre<LLOQ<LLOQ (EoC1)
post40.694
016pre<LLOQ
post205.634
018pre9.60322.08414.16911.73110.379
(EoC4)
post322.557340.709
Expansion Cohort 4:
280 mg q7d
019pre9.85711.805<LLOQ (EoC2)
post153.973
020pre8.58611.278
post110.625
021pre5.966<LLOQ<LLOQ (C2D15)
post40.352
CohortSubject IDDosingC1D8C1D15C1D22C2D1C3D1C4D1EOT
Cohort 1:
80 mg q4d
002pre8.75111.693<LLOQ (EoC2)
post12.323
003pre<LLOQ17.318
post<LLOQ30.096
004pre<LLOQ<LLOQ
post<LLOQ
Cohort 2: 120 mg q4d005pre7.18
post37.68
006pre<LLOQ10.104<LLOQ11.223
post66.156
008pre22.243
post392.01
Cohort 3: 180 mg q4d010pre43.226
post324.265
011pre11.61619.265
post11.705
012pre<LLOQ<LLOQ6.402
(EoC4)
post96.35485.834
013pre10.37441.9646.787
post
Expansion Cohort 3: 180 mg q4d014pre11.442
post60.605
017pre10.425-5.708<LLOQ6.264-
post89.884
Cohort 4: 280 mg q7d015pre<LLOQ<LLOQ (EoC1)
post40.694
016pre<LLOQ
post205.634
018pre9.60322.08414.16911.73110.379
(EoC4)
post322.557340.709
Expansion Cohort 4:
280 mg q7d
019pre9.85711.805<LLOQ (EoC2)
post153.973
020pre8.58611.278
post110.625
021pre5.966<LLOQ<LLOQ (C2D15)
post40.352

Abbreviations: EOT, end of treatment; EoC, end of cycle; q, every; d, days; LLOQ, lower limit of quantitation.

Table 3.

Afatinib Concentration (ng/mL) in Blood at Indicated Time Points

CohortSubject IDDosingC1D8C1D15C1D22C2D1C3D1C4D1EOT
Cohort 1:
80 mg q4d
002pre8.75111.693<LLOQ (EoC2)
post12.323
003pre<LLOQ17.318
post<LLOQ30.096
004pre<LLOQ<LLOQ
post<LLOQ
Cohort 2: 120 mg q4d005pre7.18
post37.68
006pre<LLOQ10.104<LLOQ11.223
post66.156
008pre22.243
post392.01
Cohort 3: 180 mg q4d010pre43.226
post324.265
011pre11.61619.265
post11.705
012pre<LLOQ<LLOQ6.402
(EoC4)
post96.35485.834
013pre10.37441.9646.787
post
Expansion Cohort 3: 180 mg q4d014pre11.442
post60.605
017pre10.425-5.708<LLOQ6.264-
post89.884
Cohort 4: 280 mg q7d015pre<LLOQ<LLOQ (EoC1)
post40.694
016pre<LLOQ
post205.634
018pre9.60322.08414.16911.73110.379
(EoC4)
post322.557340.709
Expansion Cohort 4:
280 mg q7d
019pre9.85711.805<LLOQ (EoC2)
post153.973
020pre8.58611.278
post110.625
021pre5.966<LLOQ<LLOQ (C2D15)
post40.352
CohortSubject IDDosingC1D8C1D15C1D22C2D1C3D1C4D1EOT
Cohort 1:
80 mg q4d
002pre8.75111.693<LLOQ (EoC2)
post12.323
003pre<LLOQ17.318
post<LLOQ30.096
004pre<LLOQ<LLOQ
post<LLOQ
Cohort 2: 120 mg q4d005pre7.18
post37.68
006pre<LLOQ10.104<LLOQ11.223
post66.156
008pre22.243
post392.01
Cohort 3: 180 mg q4d010pre43.226
post324.265
011pre11.61619.265
post11.705
012pre<LLOQ<LLOQ6.402
(EoC4)
post96.35485.834
013pre10.37441.9646.787
post
Expansion Cohort 3: 180 mg q4d014pre11.442
post60.605
017pre10.425-5.708<LLOQ6.264-
post89.884
Cohort 4: 280 mg q7d015pre<LLOQ<LLOQ (EoC1)
post40.694
016pre<LLOQ
post205.634
018pre9.60322.08414.16911.73110.379
(EoC4)
post322.557340.709
Expansion Cohort 4:
280 mg q7d
019pre9.85711.805<LLOQ (EoC2)
post153.973
020pre8.58611.278
post110.625
021pre5.966<LLOQ<LLOQ (C2D15)
post40.352

Abbreviations: EOT, end of treatment; EoC, end of cycle; q, every; d, days; LLOQ, lower limit of quantitation.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close